Analysis of the prevalence and drug resistance of non tuberculosis mycobacterium in Tangshan from 2016 to 2021

doi:10.19871/j.cnki.xfcrbzz.2023.06.011

Abstract

Abstract: Objective To analyze the prevalence and drug resistance of non tuberculosis mycobacterium(NTM) in Tangshan area, and to provide a basis for the prevention and treatment of NTM disease. Method Through a retrospective study, the NTM isolation rate and drug sensitivity test results of Tangshan area from January 2016 to December 2021 were collected. The trend of NTM isolation rate and corresponding bacterial composition ratio were analyzed by trend testing. The difference in NTM drug resistance rate was compared through χ² test. Result A total of NTM 390 strains were isolated from sputum samples of 2487 suspected tuberculosis patients, and the separation rate was 15.68%. The isolation rates of NTM each year were 13.89%, 14.12%, 14.36%, 17.44%, 15.69%, and 18.37%, respectively. The top three dominant strains in NTM were Mycobacterium intracellularis (62.31%), Mycobacterium kansas (18.72%), and Mycobacterium abscessus (9.49%). The order of resistance rate of single anti NTM drugs was imipenem and cilastatin(IC) (80.3%)> doxycycline(DOX) (55.49%)> minocycline(MNO) (43.35%)>sulfamethazole(SMZ) (28.32%)> cefoxitin(FOX) (24.86%)> tobramycin(TOB) (17.92%)> ethambutol(EMB) (14.45%)> rifampin(RFP) (10.98%)> azithromycin(AZM) (9.83%)> gatifloxacin(GAT) (8.67%)> rifabutin(RFb) (8.09%)> linezolid(LZD) (7.51%)> clarithromycin(CLA) (4.62%)= amikacin(AMK) (4.62%)> moxifloxacin(MXF) (1.73%). The trend test results showed a statistically significant increase in the resistance rate to IC、DOX(χ²=23.204,4.349, P<0.05). Conclusion Mycobacterium intracellularis, Mycobacterium Kansas, and Mycobacterium abscessus were the dominant NTM strains in Tangshan area. The resistance rates of some anti-NTM drugs are on the rise, and attention should be paid to the diagnosis and rational use of NTM infection in clinical diagnosis and treatment.

Key words: Mycobacteria, Non tuberculosis mycobacterium, Susceptibility assay, Isolation rate, Drug resistance rate

CLC Number:

R183.7

Liu Haitao, Tian Jie, Han Yunyan, Zhao Junpeng. Analysis of the prevalence and drug resistance of non tuberculosis mycobacterium in Tangshan from 2016 to 2021[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(6): 58-62.

References

[1] 曾旋, 陆坚, 徐宇翔, 等. 非结核分枝杆菌菌种鉴定技术研究进展[J]. 结核病与肺部健康杂志, 2019, 8(2): 146-148.
[2] DONOHUE MJ.Increasing nontuberculous mycobacteria reporting rate and species diversity identified in clinical laboratory reports[J]. BMC Infect Dis, 2018, 18(1): 163-169.
[3] 赵雁林, 逄宇. 结核病实验室检验规程[M]. 北京: 人民卫生出版社, 2015: 39-44, 53-57.
[4] 唐神结,高文. 临床结核病学[M]. 2版. 北京:人民卫生出版社, 2019: 1026-1046.
[5] 罗明, 张汇征, 李桓, 等. 重庆市2016-2017年非结核分枝杆菌流行状况分析[J]. 国际检验医学杂志, 2019, 40(10): 1178-1182.
[6] 朱业蕾, 潘爱珍, 周琳, 等. 浙江省非结核分枝杆菌流行状况及耐药性分析[J]. 预防医学, 2021, 33(1): 6-10.
[7] 杨栗坤, 曹彦, 曹艳龙, 等. 结核病专科非结核分枝杆菌肺病菌种分布及病例特点研究[J]. 中国人兽共患病学报, 2018, 34(12): 1137-1141.
[8] SANTIN M, BARRABEIG I, MALCHAIR P, et al.Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994-2014[J]. Emerg Infect Dis, 2018,24(6): 1091-1094.
[9] 刘红伟, 李晓非, 苏俊华, 等. 昆明市75例非结核分枝杆菌鉴定及药敏结果分析[J/CD]. 中华临床实验室管理电子杂志, 2020, 8(3): 170-174.
[10] WINTHROP K L, MARRAS T K, ADJEMIAN J, et al.Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large United States Managed Care Health Plan, 2008-2015[J]. Ann AM Thorac Soc, 2020, 17(2): 178-185.
[11] 杨新宇, 张洁, 易俊莉,等. 2009和2019年北京市非结核分枝杆菌流行特征比较[J]. 首都公共卫生, 2021, 15(6): 333-337.
[12] 赵东阳, 王少华, 苏茹月, 等. 2013-2018年河南省耐药监测点非结核分枝杆菌流行特征分析[J]. 中国人兽共患病学报, 2021, 37(2): 128-132, 187.
[13] 张海霞, 黄菁, 肖园园, 等. 南京地区2017-2020年结核及非结核分枝杆菌菌株分布及耐药情况分析[J]. 传染病信息, 2022, 35(3): 259-263.
[14] 陈华, 胡锦兴, 陈品儒, 等. 广州市非结核分枝杆菌流行状况与菌种分布特征:基于 2018-2019年数据[J]. 分子影像学杂志, 2021, 44(2): 378-382.
[15] 李文彬, 胡培磊, 陈忠南, 等.湖南省525株非结核分枝杆菌临床分离株的菌种鉴定与流行特征[J]. 中国人兽共患病学报, 2022, 38(5): 417-422.
[16] 钟业腾, 陈灼霖, 王洁莹, 等. 海南省肺部感染患者非结核分枝杆菌菌种鉴定分析[J]. 疾病监测, 2022, 37(8): 1053-1058.
[17] 陈华, 方伟军, 胡锦兴, 等. 两种常见缓慢生长型非结核分枝杆菌肺病的胸部CT征象比较[J/CD]. 新发传染病电子杂志, 2021, 6(4): 311-314.
[18] 夏丹丹,吴联朋. 2016年-2021年温州地区967株非结核分枝杆菌菌种鉴定结果分析[J].中国卫生检验杂志, 2022, 32(9): 1065-1068.
[19] 潘建华, 石国民, 彭雪峰, 等. 长沙地区2012-2017年非结核分枝杆菌流行状况分析[J].国际检验医学杂志, 2018, 39(20): 2496-2498.
[20] 沙巍, 肖和平. 再议非结核分枝杆菌的危害性[J]. 中华结核和呼吸杂志, 2018, 41(2): 83-85.
[21] 岳午阳,郭艳,李同心,等. 龟分枝杆菌病误诊为结核病和麻风病误诊为非结核分枝杆菌病2例病例分析[J/CD]. 新发传染病电子杂志, 2021, 6(4): 348-351.
[22] 罗佳, 喻秋菊, 林钰灵, 等. 2016-2021年四川地区非结核分枝杆菌感染临床特点分析[J]. 四川大学学报(医学版) , 2022, 53(5): 890-895.
[23] 茹晓, 范恒建.非结核分枝杆菌肺病的菌种分布及耐药性分析[J].中国医药指南, 2023, 21(23):21-24.
[24] 封彬彬, 金锋, 景辉, 等. 山东地区439株非结核分枝杆菌临床分离株菌种鉴定及耐药情况[J]. 中国防痨杂志, 2021, 43(5): 516-520.
[25] 中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(11): 918-946.
[26] NATALIA F GDC, FERNANDO P, SATO DN, et al.Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41)[J]. Antimicrob Chemother, 2018, 73(4): 862-866.
[27] 张卫, 伍国强, 廖远军, 等. 积雪草酸联合亚胺培南对产 KPC-2 耐药肠杆菌的体外抗菌作用[J]. 中国动物检验, 2023, 40(8): 94-102.
[28] 张雪芹, 张崇威, 韩立, 等. 鸡蛋中多西环素残留测定不确定度评定[J].中国兽药杂志, 2023, 57(6): 57-65.